Literature DB >> 28745565

Advances in adult acute lymphoblastic leukemia therapy.

Ibrahim Aldoss1, Anthony S Stein1.   

Abstract

Progress in adult acute lymphoblastic leukemia (ALL) treatment has been met with challenge until recently. A steady improvement in outcomes is being witnessed among adults with ALL, and it will be enhanced further with early referral of newly diagnosed ALL patients to specialized centers, enrolling more ALL adults in clinical trials, adopting pediatric-inspired ALL regimens in younger adults, tailoring treatments according to minimal residual disease response and disease genetics, incorporating novel therapies and tyrosine kinase inhibitors in frontline regimens, early referral to transplant when indicated, expanding the donor pool, and developing more effective salvage therapies for relapsed/refractory ALL. In this review, we will discuss the most significant advances in treating adult ALL observed in the last five years that have the potential to enhance adult ALL treatment and outcome.

Entities:  

Keywords:  ALL; acute; adult

Mesh:

Substances:

Year:  2017        PMID: 28745565     DOI: 10.1080/10428194.2017.1354372

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.

Authors:  Jason H Rogers; Rohit Gupta; Jaime M Reyes; Michael C Gundry; Geraldo Medrano; Anna Guzman; Rogelio Aguilar; Shannon E Conneely; Tidie Song; Cade Johnson; Sean Barnes; Carlo D D Cristobal; Kristen Kurtz; Lorenzo Brunetti; Margaret A Goodell; Rachel E Rau
Journal:  Blood Adv       Date:  2021-10-12

2.  Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.

Authors:  Mengping Xi; Shanshan Guo; Caicike Bayin; Sophie Rousseaux; Saadi Khochbin; Jian-Qing Mi; Jin Wang; Lijun Peng; Florent Chuffart; Ekaterina Bourova-Flin
Journal:  Front Med       Date:  2021-10-20       Impact factor: 9.927

3.  Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study.

Authors:  Amy Cole; Daniel R Richardson; Karthik Adapa; Amro Khasawneh; Norah Crossnohere; John F P Bridges; Lukasz Mazur
Journal:  JMIR Res Protoc       Date:  2022-06-29

4.  Transcriptome Profiling and Cytological Assessments for Identifying Regulatory Pathways Associated With Diorcinol N-Induced Autophagy in A3 Cells.

Authors:  Xiao-Long Yuan; Xiu-Qi Li; Kuo Xu; Xiao-Dong Hou; Zhong-Feng Zhang; Lin Xue; Xin-Min Liu; Peng Zhang
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

5.  Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Massimiliano Bonifacio; Cristina Papayannidis; Federico Lussana; Nicola Fracchiolla; Mario Annunziata; Simona Sica; Mario Delia; Robin Foà; Giovanni Pizzolo; Sabina Chiaretti
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

6.  P38 MAPK/AKT signalling is involved in IL-33-mediated anti-apoptosis in childhood acute lymphoblastic leukaemia blast cells.

Authors:  Yiqian Wang; Hanyi Hou; Zhongping Liang; Xuexin Chen; Xindan Lian; Jie Yang; Zeyu Zhu; Huanmin Luo; Haibo Su; Qing Gong
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  Extracellular vesicles carrying miRNA-181b-5p affects the malignant progression of acute lymphoblastic leukemia.

Authors:  Wei Yan; Li Song; Huihan Wang; Wei Yang; Liang Hu; Ying Yang
Journal:  J Transl Med       Date:  2021-12-18       Impact factor: 5.531

8.  [Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia].

Authors:  B Q Tang; Z H Cai; D N Lin; Z X Wang; X J Liang; Z P Fan; F Huang; Q F Liu; H S Zhou
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

Review 9.  Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission.

Authors:  Shukaib Arslan; Vinod Pullarkat; Ibrahim Aldoss
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

10.  PAQR3 inhibits proliferation and aggravates ferroptosis in acute lymphoblastic leukemia through modulation Nrf2 stability.

Authors:  Ling Jin; Laigen Tong
Journal:  Immun Inflamm Dis       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.